Redefining autologous regenerative medicine

Matricelf is a pioneering biotechnology company developing a platform for autologous matrix and cells implants for a wide range of medical conditions. The company was established in 2019 by Professor Tal Dvir of the Laboratory for Tissue Engineering and Regenerative Medicine from Tel Aviv University. Our patented technology is a product of eight years of research and $12 million in grants.

Key facts about matricelf

10
Employees
$12M
Research grants*
2019
Founded
2
Patents
5
Awards

* Tel Aviv University, Prof Dvir laboratory

Meet the team

Board of Directors

READ MORE

Doron Birger – Chairman of the Board

READ MORE

Prof. Ruth Arnon

READ MORE

Tal Dvir, PhD – CSO

READ MORE

Neomi Enoch

READ MORE

Stanley Hirsch

READ MORE

Suzana Nahum-Zilberberg

READ MORE

Alon Sinai – COO

Advisory Board

READ MORE

Dr. Eckhard von Keutz

READ MORE

Dr. Nicholas Theodore, M.D

READ MORE

Prof. Mark Tuszynski

READ MORE

Dr. Kapil Bharti

READ MORE

Adam Wollowick

READ MORE

Brock Reeve

Team

READ MORE

Asaf Toker, MD – CEO

READ MORE

Tal Dvir, PhD – CSO

READ MORE

Alon Sinai – COO

READ MORE

Sigal Russo, CFO

READ MORE

Tal Ben Neriah, Director of Operations

READ MORE

Tamar Harel Adar, PhD – VP R&D

Doron Birger – Chairman of the Board

Doron serves as the chairman and a director in a variety of technology companies, mainly in medical device companies.
In the past, Doron served as the CEO of Elron (Nasdaq: ELRNF, TASE: ELRN) and as the chairman and director of Given Imaging (previously traded at Nasdaq: GIVN; TASE: GIVN) until it was sold to Covidien (now Medtronic) for approximately USD 1 billion.

Prof. Ruth Arnon

Prof. Ruth Arnon Formerly Vice-President of the Weizmann Institute of Science (1988-1997), Professor Arnon is an internationally known immunologist. Along with Prof. Michael Sela, she conceptualized and developed Copaxone®, a drug for the treatment of multiple sclerosis which was approved by the U.S. Food and Drug Administration and is presently marketed worldwide.

Prof. Arnon has made significant contributions in the fields of vaccine development, cancer research and to the study of parasitic diseases. She has served as President of the European Federation of Immunological Societies (EFIS), and as Secretary-General of the International Union of Immunological Societies (IUIS).

Prof. Arnon is the recipient of numerous international and Israeli awards including the prestigious Israel Prize. She is a member of the Israel Academy of Sciences, where she served as President from 2010-2015.

Tal Dvir, PhD – CSO

Professor Dvir obtained his Ph.D. in Biotechnology Engineering from Ben Gurion University of the Negev in Israel. His Ph.D. research focused on cardiac tissue engineering and regeneration. Prof. Dvir continued his postdoctoral studies in the laboratory of Professor Robert Langer in the Department of Chemical Engineering at MIT. His postdoctorial research focused on nanotechnological strategies for engineering complex tissues. In 2011, Professor Dvir was recruited by the Department of Biotechnology and the center for Nanotechnology at Tel Aviv University to establish the Laboratory for Tissue Engineering and Regenerative Medicine. In 2013, he joined the newly established Department of Materials Science and Engineering at Tel Aviv University, where he has also served as an Associate Professor in the Department of Biotechnology since 2015.

Neomi Enoch

Neomi Enoch, CPA, MBA Neomi is a business consultant, bringing a vast experience as a CFO in global companies traded at NASDAQ and Tel Aviv stock exchange.

Neomi led the IPO of Parter communication at NASDAQ, and The IPO of Mul-T-Lock in Tel Aviv Stock Exchange and raised funds from capital market as CFO of Meuhedet HMO and Supesal Ltd.

Neomi serves as a director at Mekorot Water Company, Kalil industries Ltd, Exel solutions group and S.R. Accord Ltd

Neomi is a CPA holds an M.B.A from Bradford University, cum laud and B.A from Tel Aviv University.

Stanley Hirsch

Stanley Hirsch is a biotech and pharma CEO and Board Director with significant experience across biopharmaceutical and agricultural biotech fields.  He has extensive executive and board level experience in private and publicly listed companies on US and UK exchanges, direct experience raising capital and leading Mergers & Acquisitions.

Suzana Nahum-Zilberberg

Suzana Nahum-Zilberberg is a seasoned executive with a vast managerial and leadership experience in the healthcare industry across global companies and early-stage companies. With financial expertise and experience as a board member in various companies.

Ms. Nahum-Zilberberg is a strategic advisor and the Chairman of The Activity Based Therapy (ABT) Center Foundation for Neurorehabilitation. She served as the CEO of BioLight Life Sciences Ltd. (BOLT/TASE) between the years 2011-2020, Prior to joining BioLight, Ms. Nahum-Zilberberg held several senior positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO.

Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and a M.B.A. degree, both from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.

Alon Sinai – COO

Alon Sinai brings over 25 years of operational and managerial experience in medical corps of the Israeli Defense Forces. He holds a Master’s degree in Health Systems Management and a Bachelor’s degree in emergency medicine.

Dr. Eckhard von Keutz

Dr Von Keutz is the Chairman of the Advisory Board of the Fraunhofer Institute of Toxicology and Experimental Medicine (Hannover, Germany); Member of the Executive Council at Center of Healthcare Innovation (US); Member of the Advisory Committee for Pharmacologically Active Substances and Veterinary Drugs of the German Federal Institute for Risk Assessment; Member of the CAAT Advisory Board (Europe); Member of the Industrial Advisory Board (IAB) of the European Organ-on-Chip Society (EUROoCS).

Dr. Nicholas Theodore, M.D

Dr. Theodore is a Professor of Neurosurgery and the director of the Johns Hopkins Neurosurgical Spine Center. He is one of the world recognized expert in brain and spinal cord injury, minimally invasive spine surgeries and robotics.

Dr. Theodore has written or co-authored 30 book chapters, over 180 peer-reviewed journal articles and is co-holder of 10 patents for medical devices and procedures. His research focuses on trauma, spinal cord injuries, robotics and developing an understanding of the genetic and molecular basis of spinal diseases.

Image: Johns Hopkins Medicine

Prof. Mark Tuszynski

Prof. Mark Tuszynski, a world-renowned neurologist and researcher, is the Director of The Center for Neural Repair, University of California, San Diego.
Mark is considered a leading researcher in the field of spinal cord injury treatment and his laboratory focuses on research in the field of neuronal regeneration in general and spinal cord injuries in particular.
He has published numerous articles in the leading scientific journals and has received a number of prestigious research grants in recent years.

Photo source: UC San Diego Health

Dr. Kapil Bharti

Dr. Kapil Bharti is a senior researcher at the National Institutes of Health (“NIH”), an expert in the use of induced pluripotent stem cells (iPSC) in regenerative medicine and the development of cellular therapies.

Dr. Bharti’s laboratory at the NIH recently received from the Food and Drug Administration (FDA) the first approval in U.S. history to advance to a clinical trial in humans in the treatment of autologous iPSC, for Age-related Macular Degeneration (AMD).

Dr. Bharti received several prestigious awards, he serves as a consultant to several companies in the field and has participated in the writing of numerous scientific publications.

Adam Wollowick

Dr Wollowick is the Sr. Director of Business Development at Stryker Spine. At Stryker, Adam is focusing on mergers and acquisitions and also has responsibility for the Spine Division’s Strategy and Business Intelligence functions.

Dr. Wollowick is board-­certified by the American Board of Orthopedic Surgery. He is a member of the American Academy of Orthopedic Surgeons, the North American Spine Society and the Scoliosis Research Society.

Adam worked as an attending surgeon in the Department of Orthopedic Surgery at Montefiore Medical Center and held the title of Assistant Professor of Orthopaedic Surgery at the Albert Einstein College of Medicine, Bronx, NY, served as the Assistant Residency Program Director and was the Director of Spinal Research.

His award-­winning research has been presented nationally and internationally at major orthopaedic and spine society meetings and has been published in peer-­reviewed journals.

Dr. Wollowick received his MD in 2001 with Special Distinction in Research from the Albert Einstein College of Medicine, Bronx, NY. He completed a Masters of Business Administration in 2014 from the Yale School of Management, with a focus on Leadership in Healthcare Management.

Brock Reeve

Brock Reeve has been the Executive Director of the Harvard Stem Cell Institute since 2006. The Institute invests in research at Harvard and its hospitals with the goal of developing new curative medicines. Brock is also the CEO of IVIVA Medical, a startup company focused on organ regeneration.  He is a co-founder of Elevian, a startup addressing healthy aging, and is a Director of Thrive Bioscience, a tools company serving the cell culturing market.  He is also an Advisor to the Petit Institute at Georgia Tech University and on the Board of the Pioneer Charter School of Science in Everett, MA.

Asaf Toker, MD – CEO

Dr. Toker is a seasoned CEO with a proven track record in the biotechnology and healthcare industries. He possesses strong business development skills with prior experience in medical devices, R&D, and Life Sciences. Dr. Toker is a pediatrician and also has a degree in Health Systems Management and MSc in Biotechnology Engineering from Ben Gurion University of the Negev.

Dr Toker served in several executive positions in the private and public healthcare system and served as a director in several biotechnology and medical device companies.

Tal Dvir, PhD – CSO

Professor Dvir obtained his Ph.D. in Biotechnology Engineering from Ben Gurion University of the Negev in Israel. His Ph.D. research focused on cardiac tissue engineering and regeneration. Prof. Dvir continued his postdoctoral studies in the laboratory of Professor Robert Langer in the Department of Chemical Engineering at MIT. His postdoctorial research focused on nanotechnological strategies for engineering complex tissues. In 2011, Professor Dvir was recruited by the Department of Biotechnology and the center for Nanotechnology at Tel Aviv University to establish the Laboratory for Tissue Engineering and Regenerative Medicine. In 2013, he joined the newly established Department of Materials Science and Engineering at Tel Aviv University, where he has also served as an Associate Professor in the Department of Biotechnology since 2015.

Alon Sinai – COO

Alon Sinai brings over 25 years of operational and managerial experience in medical corps of the Israeli Defense Forces. He holds a Master’s degree in Health Systems Management and a Bachelor’s degree in emergency medicine.

Sigal Russo, CFO

Sigal Russo is a seasoned professional financial leader, bringing over 16 years of experience in key managerial positions in global, public Biotech and Pharmaceutical companies as well as in early-stage start-up companies, having previously worked for Mobilicom Ltd (ASX: MOB), OWC Pharmaceutical Research Corp. (OTCQB: OWCP) and Rosetta Genomics (NASDAQ: ROSG). Ms. Russo was also an audit manager at Ernst & Young in Israel, specializing in audits of companies from various sectors,  from 2004 to 2008. Ms. Russo holds a BA in Economics and Accounting, from the Ruppin Academic College.

Tal Ben Neriah, Director of Operations

Tal holds a MSc. in Materials Engineering and Nanotechnology and a BSc. in Life and Medical Sciences, both from Tel Aviv University.
Tal worked for more than eight years at CollPlant (NASDAQ: CLGN), a medical device company focused on regenerative medicine, as product development engineer, project manager and program manager.
Tal led multidisciplinary activities from early development to regulatory approval including clinical phase of the company’s two commercial products and we are sure that Tal will help us achieve our research and development goals.

Tamar Harel Adar, PhD – VP R&D

Tamar Harel Adar, PhD brings years of experience in Biotechnology, having previously worked for CollPlant biotechnology (NASDAQ: CLGN) and Cellect Biotherapeutics (NASDAQ: APOP). Tamar has completed her Biotechnology Engineering doctoral studies at Ben Gurion University of the Negev.